BCM
NEO icon

BluePath Capital Management’s NeoGenomics NEO Stock Holding History

BluePath Capital Management’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,407
Closed -$29.6K – 249
2023
Q3 		$29.6K Buy
+2,407
New +$35.8K 0.03% 290

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BluePath Capital Management's NEO Position: Q4 2023 in Review

BluePath Capital Management sold out of NeoGenomics (NEO) in Q4 2023, closing a stake of 2,407 shares — an estimated $29.6K sold.

BluePath Capital Management first reported a position in NEO in Q3 2023 and held it in 1 quarter. The position peaked at $29.6K in Q3 2023. 287 funds tracked by Wall St. Rank hold NEO as of Q4 2023.

  • BluePath Capital Management reported no remaining NeoGenomics position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 2,407 NeoGenomics shares in Q4 2023, an estimated $29.6K.
  • BluePath Capital Management first reported a position in NeoGenomics in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's NeoGenomics position peaked at $29.6K in Q3 2023.
  • 287 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.